RAD51 and central nervous system cancer: Combination treatments of TMZ with ERK5i induced significant increases in cells exhibiting pDNA-PK nuclear foci over each treatment alone (Figure 3A), which was not the case for RAD51 foci formation (Figure 3B); a known contributing factor to cellular resistance to TMZ in glioma cells [29].